Retinal Vein Occlusion – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Retinal Vein Occlusion – Pipeline Review, H2 2017’, provides an overview of the Retinal Vein Occlusion pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion

The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Retinal Vein Occlusion therapeutics and enlists all their major and minor projects

The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acucela Inc

Addmedica SAS

Aerpio Therapeutics Inc

Annexin Pharmaceuticals AB

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc

Formycon AG

Graybug Vision Inc

Kala Pharmaceuticals Inc

Lupin Ltd

Mabion SA

Novartis AG

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Regeneron Pharmaceuticals Inc

SciFluor Life Sciences LLC

ThromboGenics NV

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Retinal Vein Occlusion - Overview 8

Retinal Vein Occlusion - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Products under Development by Companies 12

Retinal Vein Occlusion - Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Retinal Vein Occlusion - Companies Involved in Therapeutics Development 22

Acucela Inc 22

Addmedica SAS 22

Aerpio Therapeutics Inc 22

Annexin Pharmaceuticals AB 23

Chengdu Kanghong Pharmaceuticals Group Co Ltd 23

Clearside BioMedical Inc 23

Formycon AG 24

Graybug Vision Inc 24

Kala Pharmaceuticals Inc 25

Lupin Ltd 25

Mabion SA 26

Novartis AG 26

Ocular Therapeutix Inc 27

Ohr Pharmaceutical Inc 27

Regeneron Pharmaceuticals Inc 28

SciFluor Life Sciences LLC 28

ThromboGenics NV 29

Retinal Vein Occlusion - Drug Profiles 30

ACU-6151 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

aflibercept biosimilar - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

aflibercept biosimilar - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

aflibercept SR - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

AKB-9778 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

AP-01 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

conbercept - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

HO-10 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

hydroxyurea - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

KPI-285 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

LKA-651 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ocriplasmin - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

OTX-TKI - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Protein to Inhibit VEGF for Ophthalmology - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ranibizumab biosimilar - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

ranibizumab biosimilar - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

ranibizumab biosimilar - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

SF-0166 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

squalamine lactate - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

sunitinib malate CR - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

triamcinolone acetonide - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Retinal Vein Occlusion - Dormant Projects 79

Retinal Vein Occlusion - Discontinued Products 80

Retinal Vein Occlusion - Product Development Milestones 81

Featured News & Press Releases 81

Jun 08, 2017: Clearside Biomedical’s TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting 81

Feb 16, 2017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion 82

Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting 82

Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion 83

Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 83

Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 84

Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 85

Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion 86

Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion 86

Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion 87

Appendix 89

Methodology 89

Coverage 89

Secondary Research 89

Primary Research 89

Expert Panel Validation 89

Contact Us 89

Disclaimer 90

List of Tables

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H2 2017 9

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products by Stage and Target, H2 2017 15

Number of Products by Stage and Mechanism of Action, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Retinal Vein Occlusion – Pipeline by Acucela Inc, H2 2017 22

Retinal Vein Occlusion – Pipeline by Addmedica SAS, H2 2017 22

Retinal Vein Occlusion – Pipeline by Aerpio Therapeutics Inc, H2 2017 22

Retinal Vein Occlusion – Pipeline by Annexin Pharmaceuticals AB, H2 2017 23

Retinal Vein Occlusion – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 23

Retinal Vein Occlusion – Pipeline by Clearside BioMedical Inc, H2 2017 24

Retinal Vein Occlusion – Pipeline by Formycon AG, H2 2017 24

Retinal Vein Occlusion – Pipeline by Graybug Vision Inc, H2 2017 25

Retinal Vein Occlusion – Pipeline by Kala Pharmaceuticals Inc, H2 2017 25

Retinal Vein Occlusion – Pipeline by Lupin Ltd, H2 2017 26

Retinal Vein Occlusion – Pipeline by Mabion SA, H2 2017 26

Retinal Vein Occlusion – Pipeline by Novartis AG, H2 2017 27

Retinal Vein Occlusion – Pipeline by Ocular Therapeutix Inc, H2 2017 27

Retinal Vein Occlusion – Pipeline by Ohr Pharmaceutical Inc, H2 2017 28

Retinal Vein Occlusion – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 28

Retinal Vein Occlusion – Pipeline by SciFluor Life Sciences LLC, H2 2017 29

Retinal Vein Occlusion – Pipeline by ThromboGenics NV, H2 2017 29

Retinal Vein Occlusion – Dormant Projects, H2 2017 79

Retinal Vein Occlusion – Discontinued Products, H2 2017 80

List of Figures

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Number of Products by Top 10 Targets, H2 2017 14

Number of Products by Stage and Top 10 Targets, H2 2017 14

Number of Products by Top 10 Mechanism of Actions, H2 2017 16

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 16

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Molecule Types, H2 2017 20

Number of Products by Stage and Molecule Types, H2 2017 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports